INDOLENT SYSTEMIC MASTOCYTOSIS
Clinical trials for INDOLENT SYSTEMIC MASTOCYTOSIS explained in plain language.
Never miss a new study
Get alerted when new INDOLENT SYSTEMIC MASTOCYTOSIS trials appear
Sign up with your email to follow new studies for INDOLENT SYSTEMIC MASTOCYTOSIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New pill aims to tame rare mast cell disease
Disease control Recruiting nowThis study tests an experimental drug called elenestinib (BLU-263) in people with indolent systemic mastocytosis, a rare condition where too many mast cells cause symptoms like flushing, itching, and stomach issues. About 534 participants will receive either the drug or a placebo…
Matched conditions: INDOLENT SYSTEMIC MASTOCYTOSIS
Phase: PHASE2, PHASE3 • Sponsor: Blueprint Medicines Corporation • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New drug avapritinib under Real-World watch for mastocytosis relief
Disease control Recruiting nowThis study follows 80 people in Germany with indolent systemic mastocytosis whose symptoms are not well controlled by current treatments. Researchers will track how avapritinib affects quality of life and symptom control over up to 24 months in everyday medical practice. The goal…
Matched conditions: INDOLENT SYSTEMIC MASTOCYTOSIS
Sponsor: Blueprint Medicines Corporation • Aim: Disease control
Last updated Jun 27, 2026 12:10 UTC
-
New study tracks daily life with rare mast cell disorder
Knowledge-focused Recruiting nowThis study watches how indolent systemic mastocytosis (ISM) affects people in everyday life. Researchers will collect information on symptoms, treatments, and quality of life from 150 adults. The goal is to better understand the disease and how it is managed, including the use of…
Matched conditions: INDOLENT SYSTEMIC MASTOCYTOSIS
Sponsor: Blueprint Medicines Corporation • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC